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ABSTRACT
Background: Selenium is found in soils and is essential for human
antioxidant defense and immune function. In Malawi, low soil
selenium and dietary intakes coupled with low plasma selenium con-
centrations in HIV infection could have negative consequences for the
health of HIV-infected mothers and their exclusively breastfed infants.
Objective: We tested the effects of lipid-based nutrient supplements
(LNS) that contained 1.3 times the Recommended Dietary Allowance
of sodium selenite and antiretroviral drugs (ARV) on maternal plasma
and breast-milk selenium concentrations.
Design: HIV-infected Malawian mothers in the Breastfeeding, Anti-
retrovirals, and Nutrition study were randomly assigned at delivery
to receive: LNS, ARV, LNS and ARV, or a control. In a subsample
of 526 mothers and their uninfected infants, we measured plasma
and breast-milk selenium concentrations at 2 or 6 (depending on the
availability of infant samples) and 24 wk postpartum.
Results: Overall, mean (6SD) maternal (range: 81.2 6 20.4 to
86.2 6 19.9 mg/L) and infant (55.6 6 16.3 to 61.0 6 15.4 mg/L)
plasma selenium concentrations increased, whereas breast-milk
selenium concentrations declined (14.3 6 11.5 to 9.8 6 7.3 mg/L)
from 2 or 6 to 24 wk postpartum (all P , 0.001). Compared with the
highest baseline selenium tertile, low and middle tertiles were posi-
tively associated with a change in maternal plasma or breast-milk
selenium from 2 or 6 to 24 wk postpartum (both P , 0.001). With
the use of linear regression, we showed that LNS that contained sele-
nium and ARV were not associated with changes in maternal plasma
and breast-milk selenium, but maternal selenium concentrations were
positively associated with infant plasma selenium at 2 or 6 and 24 wk
postpartum (P , 0.001) regardless of the study arm.
Conclusions: Selenite supplementation of HIV-infected Malawian
women was not associated with a change in their plasma or breast-milk
selenium concentrations. Future research should examine effects of
more readily incorporated forms of selenium (ie, selenomethionine) in
HIV-infected breastfeeding women. This trial was registered at clinical-
trials.gov as NCT00164736. Am J Clin Nutr 2014;99:950–6.
INTRODUCTION
The trace element selenium plays an important role in anti-
oxidant defense, cell-mediated immunity, brain and thyroid
function, and cardiovascular health (1). Overt selenium deficiency
is rare (2). Symptoms in people with very low plasma selenium
concentrations include cardiomyopathy, growth retardation, and
a greater susceptibility to infection (3). Selenium concentrations
tend to be low in HIV-infected individuals and decline as HIV
progresses (4–7). It has been hypothesized that selenium becomes
depleted in people with HIV because the body uses selenoproteins
to suppress viral replication, or the virus uses selenium to create its
own selenoenzymes (8), especially in the later stages of the disease
(9). Low selenium concentrations have been associated with
morbidity and mortality in HIV-infected populations (7, 10, 11).
These effects can be limited by slowing the progression of HIV
disease through the use of antiretroviral drugs (ARV)4. When
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plasma selenium concentrations are generally sufficient, HIV-
infected individuals who use ARV have maintained an adequate
selenium status (12). This effect is likely a result of improved
virologic control in individuals taking ARV. In settings in which
selenium concentrations are already low at a population level, it
may be necessary to combine both ARV and selenium supple-
mentation to attain adequate selenium concentrations in HIV-
infected individuals.
The selenium status varies worldwide and is largely dependent
on food-selenium concentrations, which tend to reflect the se-
lenium availability in soils (13). Malawi is among the countries
with low amounts of selenium in soils and staple foods (14, 15).
These low amounts have led to low dietary selenium intakes and
low plasma selenium concentrations in Malawian adults (16, 17).
HIV-infected Malawian women likely suffer from a double
burden of low selenium intakes and increased selenium needs
(18). This burden may be further exacerbated by the added
micronutrient requirements of pregnancy and lactation (19).
In other countries, such as Finland and Poland, where soil sele-
nium is low, the supplementation of lactating mothers with inorganic
and organic selenium has increased maternal plasma and breast-milk
concentrations as well as selenium intakes of their breastfed infants
(20, 21). The effect of supplementation with inorganic selenium
(in the form of sodium selenite) is generally smaller than that of
organic selenium (in the form of selenomethionine) (22). The ability
of oral selenium supplementation with inorganic or organic selenium
to increase selenium concentrations in HIV-infected adults has also
been shown (5, 9). In HIV-infected women, the effects of selenium
supplementation on maternal and infant selenium status have not
previously been reported to our knowledge.
The main aims of the current study were to measure the effects
of selenium supplementation and ARV, which are used for the
prevention of mother-to-child transmission, on maternal plasma
and breast-milk selenium concentrations and to look at the
subsequent intervention effects on infant plasma selenium con-
centrations. We hypothesized that women who received lipid-
based nutrient supplements (LNS), which contained 127% of the
Recommended Dietary Allowance for selenium during lactation,
would have higher plasma and breast-milk selenium concen-
trations than those who were not supplemented, and maternal
plasma selenium concentrations would be higher in mothers who
received ARV than in mothers who did not receive ARV. Our
secondary aims were to examine changes in maternal and infant
selenium concentrations over time and to study the relation
between maternal and infant selenium concentrations.
SUBEJCTS AND METHODS
Subjects and procedures
HIV-1–infected, pregnant women were recruited at antenatal
clinics in Lilongwe, Malawi, for participation in the Breastfeeding,
Antiretrovirals, and Nutrition (BAN) study from 2004 to 2009.
Mother-infant pairs were eligible if infants had a birth weight $2
kg, and mothers had a CD4+ count $250 cells/mm3 ($200 cells/
mm3 until July 2006), hemoglobin concentration $70 g/L, and no
previous ARV use (23).
With the use of a permuted-block method, mothers were ran-
domly assigned by using a 2 3 3 factorial design to 1 of 6 study
arms as shown in Figure 1 (see reference 21 for details of the
randomization procedure). Because this analysis examined in-
tervention effects on the mother, we combined the infant ARV plus
maternal LNS arm with the maternal LNS arm and the infant ARV
arm with the control arm, which resulted in the following 4 groups
that referred only to maternal interventions: LNS, ARV, LNS and
ARV, and control. Assigned interventions began at delivery and
continued through 28 wk. Mothers were counseled to exclusively
breastfeed from 0 to 24 wk postpartum and wean their infants from
24 to 28 wk postpartum. LNS were designed to meet the energy,
micronutrient, and protein needs of lactation. A daily 140-g dose of
LNS contained 75 mg selenium in the form of sodium selenite; the
complete nutrient content has been described elsewhere (24). So-
dium selenite was selected for use in LNS rather than selenome-
thionine because the producer (Nutriset) uses only vitamins and
minerals that are listed in the Codex Alimentarius and approved by
the European Union, where the company is based. The maternal
ARV intervention consisted of a highly active regimen, in-
cluding zidovudine and lamuvidine as a single tablet (Combivir;
GlaxoSmithKline) plus one or more other drugs (25). Mothers
were initially given nevirapine as the third drug in their regimen.
Nevirapine was discontinued in February 2005 and replaced
with nelfinavir (Viracept; Roche). In January 2006, nelfinavir
was replaced by lopinavir plus ritonavir (Kaletra; Abbott).
Blood and breast-milk samples were collected during regular
study visits at 2, 6, and 24 wk postpartum. Plasma was separated
from red blood cells within 60 min and kept at 2708C. Whole
breast-milk samples were also frozen. Mothers were asked to
report their adherence to LNS and ARV regimens at 1, 4, 8, and
21 wk. A questionnaire on socioeconomic characteristics was
administered to mothers during screening.
To measure the effects of interventions on maternal and infant
selenium concentrations, we selected a subsample who had
breast-milk andmaternal and infant plasma samples available at 2
time points, either at 2 and 24 wk (n = 358) or 6 and 24 wk (n =
168) postpartum. We originally planned to use samples from 2
and 24 wk postpartum to determine selenium concentrations as
close to the beginning and end of supplementation as possible.
We added 6 wk to the baseline group because some infants had
inadequate quantities of stored plasma at 2 wk postpartum. We
excluded multiple births and infants who were HIV positive.
With the selected sample size, we have 83% power to detect an
8-mg/L mean difference in maternal plasma selenium concen-
trations between study arms.
FIGURE 1. Randomly assigned Breastfeeding, Antiretrovirals, and Nutrition study arms and collapsed arms used in the analysis. ARV, antiretroviral drugs;
LNS, lipid-based nutrient supplements; LNS-ARV, antiretroviral drugs and lipid-based nutrient supplements.
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Ethical approval for the study was obtained from the Malawi
National Health Science Research Committee and the in-
stitutional review boards at the University of North Carolina at
Chapel Hill and the US CDC.
Laboratory analysis
Plasma and breast-milk selenium concentrations were mea-
sured at the USDA–Agriculture Research Service, Grand Forks
Human Nutrition Research Center by using automated electro-
thermal atomic absorption spectrophotometry with a reduced
palladium matrix modifier and an instrument equipped with
L’Vov platforms and automated Zeaman-effect background
correction (26). A daily calibration set for each batch was pre-
pared by using certified standards (Alfa Aesar; Perkin Elmer).
Calibration standards were analyzed at the beginning and end of
each daily batch and at a 10% frequency within each batch.
Plasma and breast-milk matrix effects were examined by using
quantitative standards (National Institute of Standards and
Technology) and spiked sample recovery tests. Laboratory tests
of the LNS provided to mothers confirmed that the supplement
contained the stated quantity (75 mg) of selenium.
Statistical analysis
We used a cutoff of the plasma selenium concentration at,80
mg/L to indicate a low selenium status in mothers. Adults with
plasma selenium concentrations w80 mg/L appear to express
major selenoproteins at maximal concentrations (27). We chose
to report infant intakes of selenium from breast milk because
there is no standard selenium adequacy for this age group. Infant
selenium intake from breast milk was calculated by multiplying
the mean breast-milk selenium concentration by the estimated
breast-milk intake at each age (710 g/d at 2 or 6 wk postpartum
and 780 g/d at 24 wk 24 wk postpartum) (28). The proportion
with the recommended normative intake from the WHO/FAO
(6 mg/d from 0 to 6 mo of age) (3) and adequate intake from the
Institute of Medicine (15 mg/d from 0 to 6 mo of age) (19) was
determined for each time point.
Our initial analysis tested intervention effects overall. We
subdivided the sample into tertiles to determine whether in-
terventions had a differential effect on the change in selenium by
the baseline selenium concentration. The LNS used in this study
contained selenite, which is not as bioavailable as organic se-
lenium (ie, selenomethionine), and thus, we expected to see the
strongest effects of supplementation in mothers with the lowest
baseline concentrations. Means and proportions of background
characteristics were compared between study arms by using
a 2-factor ANOVA for continuous variables and logistic re-
gression for categorical variables. Mean selenium concentrations
from 2 or 6 to 24 wk postpartum were compared by using paired
t tests. A 2-factor ANOVA was used to test effects of study in-
terventions within tertiles. Multivariable linear regression
models, with the timing of the early visit (2 or 6 wk postpartum)
controlled for, were used to examine effects of BAN in-
terventions and the baseline tertile on selenium concentrations in
maternal plasma and breast milk. All analyses that examined
effects of study interventions included LNS, ARV, and the in-
teraction between LNS and ARV in the models. Multivariable
models were also used to study associations between maternal
and infant selenium concentrations. Statistical analyses were
conducted with Stata 12.1 software (StataCorp).
RESULTS
Characteristics of mother-infant pairs generally did not differ
by study arm, with the exception of the CD41 count at 24 wk
postpartum (Table 1). As expected, women in study arms that
received ARV had a higher median CD41 count at 24 wk
postpartum. We also examined characteristics of mother-infant
pairs in the selenium-analysis sample and those of other BAN
participants. Mothers in the selenium subsample had a higher
mean maternal age (P , 0.01) and lower mean BMI (P , 0.05),
and a greater proportion had a CD41 count ,250 cells/mL at
TABLE 1
Characteristics of mother-infant pairs in the selenium subsample by study arm1
Control (n = 175) LNS (n = 178) ARV (n = 84) LNS-ARV (n = 89) P
Mothers
Age (y) 26.5 6 5.22 26.5 6 5.3 27.3 6 5.3 26.3 6 5.3 0.60
More than a primary education (%) 37 39 37 33 0.76
BMI at 2 wk postpartum (kg/m2) 22.6 6 2.6 22.8 6 3.4 22.3 6 3.3 22.3 6 2.8 0.36
BMI ,18.5 kg/m2 at 2 wk postpartum (%) 3 5 6 8 0.33
CD4+ at baseline (cells/mL) 421 (324, 570)3 447 (318, 591) 469 (304, 601) 400 (319, 584) 0.84
CD4+ at 24 wk postpartum (cells/mL) 463 (319, 665) 491 (330, 698) 617 (439, 780) 607 (412, 796) ,0.001
CD4+ ,250 cells/mL at 24 wk postpartum (%) 10 12 3 4 0.02
No. of pregnancies 3.3 6 1.7 3.3 6 1.7 3.4 6 1.5 3.4 6 1.9 0.92
Infants
Female (%) 47 53 43 45 0.34
Birth weight (kg) 3.0 6 0.4 3.0 6 0.4 3.1 6 0.4 3.0 6 0.4 0.61
Birth length (cm) 48.3 6 1.8 48.1 6 1.9 48.3 6 2.0 48.2 6 2.2 0.78
1CD4+ counts at 24 wk postpartum included 481 participants. P values represent the overall significance for the difference in characteristics of study arms
obtained from the 2-factor ANOVA for continuous variables and logistic regression for categorical variables. Models contained an interaction term for
LNS-ARV to represent this study arm. ARV, antiretroviral drugs; LNS, lipid-based nutrient supplements; LNS-ARV, lipid-based nutrient supplements and
antiretroviral drugs.
2Mean 6 SD (all such values).
3Median; IQR in parentheses (all such values).
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24 wk postpartum (P , 0.01), than did the rest of the study
sample (see Supplemental Table 1 under “Supplemental data” in
the online issue).
Maternal LNS and ARVadherence in the subsample was high.
The proportion of mothers who reported eating the full daily dose
on the previous day ranged from 87% to 96% at 1, 4, 8, and 21 wk
postpartum, whereas the proportion of mothers who reported
taking their ARV daily for the past 3 d ranged from 87% to 94% at
the same time points.
We showed no differences in the mean change in selenium by
study arm within any tertile (Table 2). In regression analyses,
LNS that contained selenium and ARV were not associated with
a change in the selenium concentration, whereas the trend across
tertiles was positively associated with a change in maternal
plasma or breast-milk selenium from 2 or 6 to 24 wk postpartum
(see Supplemental Table 2 under “Supplemental data” in the
online issue). Because there were no intervention effects on
maternal selenium concentrations, we did not examine effects of
interventions through breast milk on infant plasma concentra-
tions.
Selenium concentrations varied widely at each time point
(Table 2). Overall, mean maternal and infant plasma selenium
concentrations increased (maternal: 81.2 6 20.4 mg/L at 2 or 6
wk postpartum to 86.2 6 19.9 mg/L at 24 wk postpartum; P ,
0.001; infant: 55.6 6 16.3 mg/L at 2 or 6 wk postpartum to
61.0 6 15.4 mg/L at 24 wk postpartum; P , 0.001), whereas
breast-milk selenium concentrations decreased (14.3 6 11.5
mg/L at 2 or 6 wk postpartum to 9.8 6 7.3 mg/L at 24 wk
postpartum; P , 0.001) significantly over time. The direction of
change in the selenium concentration differed by baseline tertile
across all 3 outcomes, with selenium concentrations increasing
in the low tertile and decreasing in the high tertile (Table 2).
On the basis of plasma selenium concentrations, we showed
that 50% and 42% of mothers had a low selenium status (,80
mg/L) at 2 or 6 and 24 wk postpartum, respectively. Mean infant
intakes of selenium from breast milk were estimated at 10.1 6
8.2 mg/d at 2 or 6 wk postpartum and 7.7 6 5.7 mg/d at 24 wk
postpartum, indicating that 30% and 39% of infants did not
achieve the FAO/WHO recommended selenium intake at 2 or 6
and 24 wk postpartum. According to the Institute of Medicine
guidelines, 85% and 91% of infants did not achieve adequate
selenium intakes from breast milk at 2 or 6 and 24 wk post-
partum.
Maternal plasma and breast-milk selenium concentrations
were strongly positively associated with infant plasma selenium
concentrations at 2 or 6 and 24 wk postpartum (Table 3). The
change in maternal plasma and breast-milk selenium from 2 or 6
to 24 wk postpartum was positively associated with the change
in the infant selenium concentration (both P , 0.001) (not
shown).
DISCUSSION
Despite good adherence to study interventions, we showed that
LNS, ARV, and LNS and ARV did not affect maternal plasma or
breast-milk selenium concentrations in the whole sample or in
women with the lowest baseline selenium tertile. The form of
selenium used in the supplement was likely one of the main
factors that limited the effect of LNS onmaternal selenium status.
Inorganic sodium selenite is somewhat less readily absorbed than
many food forms of selenium, particularly selenomethionine,
which is the dominant one. More importantly, selenite can be
incorporated only into selenoproteins. Twenty-five selenopro-
teins have been identified in humans, but many forms are present
in only some tissues [eg, 9 forms are present in breast milk (29)].
In individuals with plasma selenium concentrations $80 mg/L,
selenoproteins, such as glutathione peroxidase-3, are maximally
expressed, and supplementation with selenite cannot be effec-
tively incorporated (27). Consequently, selenite treatment pro-
duces small increases in concentrations of selenium in the
plasma and breast milk of individuals who do not have low
concentrations of the element. Unlike selenite, selenomethionine
can also be incorporated nonspecifically into general proteins in
lieu of methionine; for this reason, sources of selenomethionine
produce greater increases in tissue selenium concentrations
(20, 21, 29, 30). Good sources of selenomethionine include
selenium-enriched yeast, which can be used in supplements,
and high-protein foods produced on soils that are not deficient in
selenium. When individuals are in a steady state concentration
of selenium, the nonspecific component of plasma selenium
represents a turning-over pool that releases selenium in the form
of selenomethionine for incorporation into selenoproteins (26).
We expected that participants who received ARV would have
had higher selenium concentrations because the virus would be
suppressed and disease progression would be limited by the drugs
(12). The lack of an ARV effect in the current study was likely
explained by the high mean CD41 counts at 24 wk postpartum
across study arms, even in subjects who did not receive drugs.
Work by Rousseau et al (31) has indicated that there may be
a threshold (eg, CD41 count ,250 cells/mm3) below which
selenium concentrations begin to decline. This threshold was
crossed by few women (w8%) included in this analysis.
The direction of change in selenium concentrations in post-
partum women and infants has not been consistently established
across studies. The decline in breast-milk selenium concentra-
tions in our sample was similar to that in reports from the United
States (32), Finland (20), Niger (33), and Burundi (34) but
differed from that in studies in Belgium (35) and Japan (36),
where there were no changes over time in the selenium con-
centration of mature human milk. Kumpulainen et al (20) have
suggested that a gradual decline in breast-milk selenium con-
centration is physiologic even when maternal selenium con-
sumption is sufficient. The increase in infant plasma selenium in
this study was consistent with the results of other research, which
indicated a small decline in selenium concentration from birth to
4 mo of age and an increase through the rest of infancy and to
adulthood (37–39). The increase in maternal plasma selenium
seen in this sample differed from the results in several other
studies, in which maternal plasma selenium remained stable in
nonsupplemented women postpartum (21, 32, 40), but was in
agreement with results of studies in Niger (33) and Poland (41),
where plasma selenium increased during lactation.
Mean maternal plasma and breast-milk selenium concentra-
tions in our sample were within ranges reported in 2 reviews (2,
29). However, this result should not mask the fact that many of the
mothers in this study had plasma selenium concentrations below
those associated with maximal selenoprotein expression, which
suggested the possibility of subclinical deficiency (42). The
women also had substantially lower plasma selenium concen-
trations than HIV-infected women in Kenya (110 mg/L) and
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Tanzania (128 mg/L) (43, 44) but higher concentrations than
women of unknown HIV status in rural Malawi (62 mg/L) (16).
Breast-milk concentrations of selenium in our sample were low
compared with many of the countries in a review by Dorea (29),
including Niger (12.0 mg/L at 6 mo of age), Nigeria (24.2 mg/L
at 3 mo of age), and Zaire (19.3 mg/L at 3 mo of age) but were
similar to concentrations reported in Burundi (6.1 mg/L at 4 mo
of age). As expected on the basis of low breast-milk selenium
concentrations in mothers in the BAN study, a large proportion
of infants in the current study did not achieve adequate selenium
intakes, and estimated intakes at 24 wk postpartum were lower
than in other countries where intakes from mature milk have
been calculated (39). Infants are born with selenium reserves,
but exclusively breastfed infants need the selenium in breast
milk to maintain an adequate selenium status (29). Despite low
selenium intakes from breast milk, selenium concentrations in
BAN infants at 6 mo of age were higher than concentrations in
a mixed group of HIV-exposed and unexposed infants in Zambia
(49 mg/L at 6 mo of age) (45) and slightly lower than in infants
of HIV-infected mothers in Tanzania (69 mg/L at 6 mo of age)
(46). These concentrations indicated that at least a portion of
infants in these countries have low selenium status and could
benefit from higher selenium concentrations in maternal milk.
Three issues should be considered when interpreting these
data. First, the generalizability of our findings may have been
limited by criteria used to select the selenium subsample for this
analysis. Although there were significant differences in a few
characteristics of the selenium subsample compared with the rest
of BAN participants, differences were small and generally not
clinically important. Second, our baseline measurements were
either at 2 or 6 wk postpartum, and values were somewhat
different for these groups. However, both groups showed similar
patterns of change for maternal plasma and breast milk, and
relations between maternal and infant selenium concentrations
did not differ by the timing of the baseline measurement. Third,
we used published values for the breast-milk intake of exclusively
breastfed infants to calculate adequate selenium intakes (28).
These values were based on a small number of studies, and the
lower age range covered the period from 0 to 2 mo of age. We
suspect that breast-milk intakes at 2 wk postpartum may have
been lower than the average intake during this period, and thus,
we may have underestimated the proportion of infants who
achieved adequate intakes at this time point.
In conclusion, intervention strategies to reduce the prevalence
of a low selenium status in Malawian women’s plasma and breast
milk are needed. Recommendations to increase the intake of
selenium-rich foods would be difficult in Malawi because the
most common source of dietary selenium is maize, which is
already eaten in large quantities and contains ,7 mg Se/100 g
(15, 17). Two other strategies that might be more feasible in-
clude the use of selenium-containing crop fertilizers or the use
of organic selenium supplements. Fertilizers have proven to be
effective in another country with low soil selenium (47), and
they are widely used and frequently subsidized in Malawi. Al-
ternatively, organic selenium supplements could be provided to
women during antenatal visits and when mothers bring their
infants for immunizations. Before choosing an intervention
strategy, additional studies in HIV-infected mothers are needed
to determine the dosage of selenomethionine in fertilizers or
supplements that produces an optimal effect on plasma and milk
concentrations.
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